Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Axsome Therapeutics, Inc.
This study will evaluate AXS-05 in a randomized, double-blind, placebo-controlled study in patients with MDD. Eligible patients will be randomized in a 1:1 ratio to treatment with AXS-05 or placebo for 6 weeks.
Age
18–65
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Age 18 - 65
Currently meets DSM-5 criteria for MDD
Body Mass Index between 18 and 40 kg/m\^2, inclusive
You may not be if
Suicide risk
History of treatment resistance in current depressive episode
History of electroconvulsive therapy, vagus nerve stimulation, transcranial magnetic stimulation or any experimental central nervous system treatment during the current episode or in the past 6 months
Pregnant, breastfeeding, or planning to become pregnant or breastfeed during the study
Clareo Health | A Trial of AXS-05 in Patients With Major Depressive Disorder
